You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,420,592


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,420,592
Title:Methods of treatment using single doses of oritavancin
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Inventor(s): Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/060,811
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,420,592: A Comprehensive Analysis

Introduction

United States Patent 8,420,592, like any other patent, is a complex document that outlines the invention, its claims, and the scope of protection it offers. To fully grasp the implications and significance of this patent, it is crucial to delve into its various components and the broader patent landscape.

Patent Basics

What is a Patent?

A patent is a form of intellectual property that grants the inventor exclusive rights to make, use, and sell the invention for a specified period, typically 20 years from the filing date of the patent application[2].

Types of Patents

There are several types of patents, including utility patents, design patents, and plant patents. Utility patents, which are the most common, cover functional inventions and are likely the category under which U.S. Patent 8,420,592 falls.

The Patent Claims

Importance of Claims

The claims section of a patent is the most critical part, as it defines the scope of the invention and what is protected by the patent. Claims must be clear, concise, and supported by the description in the patent specification[3].

Claim Structure

Patent claims typically follow a specific structure:

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.
  • Method Claims: These claims describe a process or method.
  • Apparatus Claims: These claims describe a device or system.

Analyzing Claims of U.S. Patent 8,420,592

To analyze the claims of U.S. Patent 8,420,592, one would need to review the patent document itself. Here are some key points to consider:

  • Independent Claims: Identify the independent claims as they set the broadest scope of protection.
  • Dependent Claims: Understand how the dependent claims narrow down the invention.
  • Claim Language: Pay attention to the specific language used in each claim, as small variations can significantly impact the scope of protection.

Patent Scope and Coverage

Determining Scope

The scope of a patent is determined by the claims, but it is also influenced by the description and drawings provided in the patent specification. The scope defines what is protected and what is not[3].

Patent Scope Measurements

The USPTO has developed datasets and measures to analyze patent scope, including claim-level statistics and document-level statistics. These tools can help in understanding the breadth and depth of the patent's coverage[3].

Inventorship and Ownership

Determining Inventorship

Inventorship is a critical aspect of patent law. The true and only inventors must be listed on the patent application. Conception of the idea and reduction to practice are key steps in determining inventorship[2].

Implications for U.S. Patent 8,420,592

Ensuring that the correct inventors are listed on U.S. Patent 8,420,592 is essential for the patent's validity and enforceability. Incorrect or incomplete identification of inventors can lead to challenges and potential invalidation of the patent.

Obviousness-Type Double Patenting (ODP)

Definition and Impact

ODP is a doctrine that prevents the same inventor or assignee from obtaining multiple patents for the same invention or for obvious variations of the same invention. This is particularly relevant when dealing with continuation-in-part patents or patents with overlapping claims[1].

Relevance to U.S. Patent 8,420,592

If U.S. Patent 8,420,592 is part of a patent family with overlapping claims or if it is a continuation-in-part of another patent, ODP analysis would be crucial to ensure that the patent does not infringe on earlier patents within the same family.

Patent Term Adjustment (PTA)

What is PTA?

PTA is a provision that adjusts the term of a patent to compensate for delays during the prosecution process. This can extend the life of the patent beyond the standard 20-year term from the filing date[1].

Impact on U.S. Patent 8,420,592

If U.S. Patent 8,420,592 received a PTA, it would be important to understand how this adjustment affects the patent's expiration date and any ODP analysis that might be applicable.

Global Dossier and Public Search Facilities

Accessing Patent Information

Tools like the Global Dossier and the USPTO Public Search Facility provide access to detailed information about patents, including file histories, classifications, and citation data. These resources can be invaluable in analyzing the patent landscape surrounding U.S. Patent 8,420,592[4].

Small Claims Patent Court

Feasibility and Structure

There has been discussion and study on the feasibility of a small claims patent court to handle lower-stakes patent disputes more efficiently. This could potentially impact how disputes related to U.S. Patent 8,420,592 might be handled in the future[5].

Key Takeaways

  • Claims Analysis: The claims section is crucial for understanding the scope and protection offered by U.S. Patent 8,420,592.
  • Inventorship: Correct identification of inventors is essential for the patent's validity.
  • ODP and PTA: These doctrines can significantly impact the patent's term and validity.
  • Global Dossier: Utilize global dossier and public search facilities to gather comprehensive information about the patent.
  • Future Legal Landscape: Be aware of potential changes in the legal landscape, such as the establishment of a small claims patent court.

FAQs

What is the significance of the claims section in a patent?

The claims section defines the scope of the invention and what is protected by the patent, making it the most critical part of the patent document.

How is inventorship determined in U.S. patent law?

Inventorship is determined by identifying who conceived the idea and reduced it to practice. The conception step is particularly important and involves forming a definite and permanent idea of the complete and operative invention[2].

What is Obviousness-Type Double Patenting (ODP)?

ODP prevents the same inventor or assignee from obtaining multiple patents for the same invention or for obvious variations of the same invention, ensuring that patents do not overlap inappropriately[1].

How does Patent Term Adjustment (PTA) affect a patent?

PTA adjusts the term of a patent to compensate for delays during the prosecution process, potentially extending the life of the patent beyond the standard 20-year term[1].

What resources are available for searching and analyzing patents?

Resources such as the Global Dossier and the USPTO Public Search Facility provide comprehensive access to patent information, including file histories and citation data[4].

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. Determining Inventorship for US Patent Applications, Oregon State University.
  3. Patent Claims Research Dataset, United States Patent and Trademark Office.
  4. Search for patents, United States Patent and Trademark Office.
  5. U.S. Patent Small Claims Court, Administrative Conference of the United States.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,420,592

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes 8,420,592 ⤷  Subscribe TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT ⤷  Subscribe
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes 8,420,592 ⤷  Subscribe TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,420,592

PCT Information
PCT FiledAugust 29, 2009PCT Application Number:PCT/US2009/055466
PCT Publication Date:March 04, 2010PCT Publication Number: WO2010/025438

International Family Members for US Patent 8,420,592

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2337575 ⤷  Subscribe 300834 Netherlands ⤷  Subscribe
European Patent Office 2337575 ⤷  Subscribe CA 2016 00044 Denmark ⤷  Subscribe
European Patent Office 2337575 ⤷  Subscribe 41/2016 Austria ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.